Study Of Yondelis(R) In Ovarian Cancer Shows Significant Prolongation In Progression Free Survival Positive final results of the Phase III randomized pivotal study of Yondelis® in ovarian cancer were presented during the Presidential Symposium at the ESMO congress in Stockholm. ESMO selects clinical studies that may result in a change in the current standard of care for presentation at the 2008 Presidential Symposium. In total, 672 patients in 124 hospitals across 21 countries worldwide were enrolled in the pivotal study OVA-301, initiated in 2005.
Source: www.medicalnewstoday.comFDA Expands Use Of HPV Vaccine Gardasil For Vaginal, Vulvar Cancer Prevention FDA on Friday approved expanding the use of Merck's human papillomavirus vaccine Gardasil to protect against cancers of the vagina and vulva, the AP/MSNBC.com reports (AP/MSNBC.com, 9/12). According to an FDA
Source: www.medicalnewstoday.comUse Of Therapeutic Monoclonal Antibodies Increasing In Europe Despite high therapy costs and drug format limitations, the popularity of monoclonal antibodies (mAbs) is on the rise. Physicians are increasingly adopting mAbs because of their superior side effect profile, and continued research is expected to yield more innovative products. New analysis from
Source: www.medicalnewstoday.com
# posted by Network @ 4:00 PM
